Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
Journal article published in 2022 by
Shiho Chiba,
Maki Kiso,
Noriko Nakajima,
Shun Iida 
,
Tadashi Maemura,
Makoto Kuroda,
Yuko Sato,
Mutsumi Ito,
Moe Okuda,
Shinya Yamada,
Kiyoko Iwatsuki-Horimoto ,
Tokiko Watanabe,
Masaki Imai,
Tammy Armbrust,
Ralph S. Baric
and other authors.
,
Tadashi Maemura,
Makoto Kuroda,
Yuko Sato,
Mutsumi Ito,
Moe Okuda,
Shinya Yamada,
Kiyoko Iwatsuki-Horimoto ,
Tokiko Watanabe,
Masaki Imai,
Tammy Armbrust,
Ralph S. Baric
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
During a pandemic, repurposing drugs that are approved for other diseases is a quick and realistic treatment option. In this study, we found that co-administration of favipiravir and the remdesivir metabolite GS-441524 more effectively blocked SARS-CoV-2 replication in the lungs of Syrian hamsters than either favipiravir or GS-441524 alone as part of a prophylactic or therapeutic regimen.